Black Rock Inc. Clene Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Clene Inc. stock. As of the latest transaction made, Black Rock Inc. holds 180,009 shares of CLNN stock, worth $59,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares

180,009

Previous 464,218 61.22%

Holding current value

$59,402

Previous $139,000 44.6%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.28 - $0.53 $79,578 - $150,630	-284,209 Reduced 61.22%	180,009 $77,000
Q4 2023 Feb 13, 2024	BUY	$0.26 - $0.55 $8,453 - $17,882	32,513 Added 7.53%	464,218 $139,000
Q3 2023 Nov 13, 2023	BUY	$0.46 - $0.87 $109,346 - $206,806	237,709 Added 122.53%	431,705 $215,000
Q2 2023 Aug 11, 2023	BUY	$0.78 - $1.22 $5,370 - $8,399	6,885 Added 3.68%	193,996 $170,000
Q1 2023 May 12, 2023	BUY	$0.95 - $1.62 $1,772 - $3,022	1,866 Added 1.01%	187,111 $211,000

Q4 2022 Feb 13, 2023	BUY	$0.92 - $1.11 $1,144 - $1,380	1,244 Added 0.68%	185,245 $185,000
Q3 2022 Nov 14, 2022	SELL	$0.33 - $4.83 $882 - $12,920	-2,675 Reduced 1.43%	184,001 $516,000
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $1.98 Million - $3.89 Million	-944,485 Reduced 83.5%	186,676 $471,000
Q1 2022 May 12, 2022	SELL	$2.42 - $4.42 $35,150 - $64,200	-14,525 Reduced 1.27%	1,131,161 $4.46 Million
Q4 2021 Feb 10, 2022	BUY	$3.95 - $7.53 $315,842 - $602,098	79,960 Added 7.5%	1,145,686 $4.7 Million
Q3 2021 Nov 09, 2021	SELL	$6.83 - $13.58 $761,811 - $1.51 Million	-111,539 Reduced 9.47%	1,065,726 $7.28 Million
Q2 2021 Aug 11, 2021	BUY	$6.98 - $13.33 $8.22 Million - $15.7 Million	1,177,265 New	1,177,265 $13.2 Million

Others Institutions Holding CLNN

# of Institutions

Shares Held

7.44M

Call Options Held

48.1K

Put Options Held

160K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account